MORINGA OLEIFERA AS A NUTRITIONAL SUPPLEMENT ON HIV PATIENTS ON ANTIRETROVIRAL THERAPY IN NIGERIA

Not Applicable

• Conditions: HIV/AIDS

• Registration Number: PACTR201811722056449
• Lead Sponsor: KZ

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-09-25
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Other
• Sex: All
• Target Recruitment: 172

Inclusion Criteria

1.Being HIV sero-positive
2.Patients = 18 years old
3.Patients with CD4 counts = 500 cells/mm3
4.Commenced ART at least for three months (Tenofovir + Lamivudine + Efavirenz combination).
5.Be willing to give informed consent and comply with study protocol

Exclusion Criteria

1.Known allergy or intolerance to Moringa oleifera or placebo (cornstarch powder)
2.Pregnant women
3. Patients with CD4 counts > 500 cells/mm3
4.Patients with active opportunistic infection
5.Patients taking anti-coagulant, micronutrient or natural health product supplements within 30days of randomization
6.Patients with poor or suboptimal adherence to ART medication
7.For ease of monitoring and to achieve maximum compliance to study protocol, patients living outside Kano metropolis will be excluded.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in immunological status: a.CD4;Change in immunological status: b. Viral load<br><br>;Change in anthropometric parameters ( weight, BMI, waist-hip circumference & mid-arm circumference); Occurrence and frequency of opportunistic infections

Secondary Outcome Measures

Name	Time	Method
Patients’ quality of life (QoL)